Breaking News
Sort by:
Top Post
Eisai Submits Marketing Autherization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
Eisai and Biogen have announced that Eisai has submitted a marketing authorization application (MAA) for […]
Modus Therapeutics Submits Patent Application for Sevuparin in Kidney Disease
Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical […]
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib
Takeda has today announced that it has entered into an exclusive licensing agreement with HUTCHMED […]
Ferronova Secures A$11 Million to Advance Nanotech Image-guided Cancer Therapy
Australian biotech company Ferronova has announced it has secured a further A$11 million to progress […]
Priothera Announces First Patients Enrolled in Pivotal Global Study for Patients with Acute Myeloid Leukemia
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound […]
US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) […]
Evaxion Receives FDA Fast-track Designation for Personalized Cancer Immunotherapy
Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today […]
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing […]
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma
Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of […]
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Sun Pharma and Concert Pharmaceuticals today announced that they have executed a definitive agreement under […]
Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
Tallac Therapeutics, a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity […]
- MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson’s Disease Read more
- Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome Read more
- Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear Read more
- Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors Read more
- Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors Read more